ProQR Therapeutics (PRQR) Cash from Investing Activities (2013 - 2022)

ProQR Therapeutics' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $19384.7 for Q4 2022.

• In Q4 2022, Cash from Investing Activities rose 110.21% year-over-year to $19384.7; the TTM figure through Dec 2022 stood at -$748991.3 (down 50.55% YoY), while the FY2025 annual figure was -$1.2 million, up 72.72% from the prior year.
• Cash from Investing Activities came in at $19384.7 for Q4 2022 at ProQR Therapeutics, up from -$248035.5 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $19384.7 in Q4 2022 to a low of -$378902.3 in Q2 2020.
• A 5-year average of -$152865.4 and a median of -$165294.7 in 2020 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities tumbled 5158046.1% in 2019 and surged 110.21% in 2022, its largest moves.
• ProQR Therapeutics' Cash from Investing Activities stood at -$30.82 in 2018, then tumbled by 858322.67% to -$264546.2 in 2019, then soared by 46.82% to -$140690.2 in 2020, then sank by 34.98% to -$189899.2 in 2021, then surged by 110.21% to $19384.7 in 2022.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $19384.7, -$248035.5, and -$246490.1 for Q4 2022, Q3 2022, and Q2 2022 respectively.

Peer Comparison